Marc-Alexander Burmeister – President, B. Braun France
Dr Marc-Alexander Burmeister, president of B. Braun in France, shares the exciting changes to come for B. Braun globally and in France, and discusses the shifting environment of healthcare in…
For 175 years, B. Braun has been the trusted partner of healthcare facilities through its range of innovative products and services and safety, suitable for all patient treatment steps.
A family group of German origin, B. Braun specializes in the design, production and marketing of medical and surgical equipment, pharmaceutical products and related services. The Group has over 140 subsidiaries worldwide. In 2015, the Group achieved a turnover of over 6.13 billion euros with a workforce of 56,000 employees in 64 countries.
In France, B. Braun develops, manufactures and markets hospital medical devices, implants, and pharmaceutical products in the areas of surgery, infusion, intensive care and regional anesthesia.
B. Braun also accompanied home patients with chronic diseases in the fields of stoma, continence, wound care and diabetes.In 2014, B. Braun achieved a turnover of over EUR 284 million in France .
Contact
B. Braun
204 Avenue du Maréchal
92100 Boulogne
France
+33 1 41 10 53 00
+33 1 41 10 53 99
www.bbraun.fr
Dr Marc-Alexander Burmeister, president of B. Braun in France, shares the exciting changes to come for B. Braun globally and in France, and discusses the shifting environment of healthcare in…
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are working together to develop a vaccine for the novel coronavirus (COVID-19);…
Speaking exclusively to PharmaBoardroom at the International Women’s Day 2020 event at the Franco-British Chamber of Commerce in Paris, esteemed cardiologist Professor Claire Mounier-Vehier outlines why cardiovascular disease is not…
Researchers at the Institut Pasteur in Paris have become the first in Europe to fully sequence the genome of the 2019-nCoV coronavirus – putting the Institut at the forefront of…
These are worrying times for iconic French mid-cap Ipsen. Trials for palovarotene, a treatment for rare bone disorders, have been plagued by setbacks, perhaps contributing to erstwhile CEO David Meek’s…
France is home to the highest rates of vaccine mistrust in Europe, with a third of French people disagreeing that vaccines are safe, according to the Wellcome Global Monitor survey.…
With Minister of the Economy and Finance, Bruno Le Maire, emphasizing the importance of “winning the battle on data” and eccentric mathematician Cédric Villani, well in the process of drawing…
France – one of the most influential countries in the development of gene therapy– still stands as a global powerhouse in the field, with top-class institutions, a dense network of…
With a feel-good factor sweeping French innovative pharma, the country’s iconic mid-cap biopharma standard-bearers are once more on the rise. These medium-sized national champions form part of G5 Santé, a…
Francois Cornu, president of Eurofins Biomnis, and Gautier Decock, managing director of Eurofins BioPharma Product Testing in France and Belgium, come together to shed light on the company’s unique decentralized…
Nathalie Giraud, director of integrated monitoring investigator services & head of France at PPD, breaks down the strengths and weaknesses of the French clinical trials environment and stresses the importance…
The latest issue of Healthcare & Life Sciences Review France follows on from our March 2019 report and takes a closer look at the wider French life sciences value chain…
Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world pharmaceuticals stage. Privately owned, smaller and sleeker than many of its direct competitors, but…
See our Cookie Privacy Policy Here
